Zacks Investment Research lowered shares of Avanos Medical (NYSE:AVNS) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

According to Zacks, “Avanos Medical Inc. operates as a medical technology company. It offers infection prevention, surgical, respiratory, digestive health and pain management solutions. Avanos Medical Inc., formerly known as Halyard Health Inc., is headquartered in Alpharetta, Georgia. “

Several other analysts also recently commented on the stock. Morgan Stanley raised their price objective on shares of Avanos Medical from $60.00 to $62.00 and gave the stock an underweight rating in a research report on Thursday. Raymond James raised shares of Avanos Medical from a market perform rating to an outperform rating in a research report on Tuesday, August 21st. Finally, KeyCorp raised their price objective on shares of Avanos Medical from $66.00 to $75.00 and gave the stock an overweight rating in a research report on Wednesday, August 8th.

NYSE:AVNS traded down $0.02 on Friday, reaching $59.44. 341,982 shares of the stock traded hands, compared to its average volume of 374,079. The company has a market capitalization of $3.24 billion, a PE ratio of 25.29 and a beta of 1.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.18 and a current ratio of 2.48. Avanos Medical has a 1-year low of $41.51 and a 1-year high of $72.96.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, August 7th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. The company had revenue of $160.90 million during the quarter, compared to the consensus estimate of $157.37 million. Avanos Medical had a net margin of 11.85% and a return on equity of 7.61%. Research analysts predict that Avanos Medical will post 1.87 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in shares of Avanos Medical in the 2nd quarter worth $136,000. CENTRAL TRUST Co bought a new position in shares of Avanos Medical in the 3rd quarter worth $167,000. Bank of Montreal Can bought a new position in shares of Avanos Medical in the 3rd quarter worth $197,000. McQueen Ball & Associates Inc. bought a new position in shares of Avanos Medical in the 3rd quarter worth $268,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Avanos Medical in the 3rd quarter worth $704,000. Institutional investors own 84.85% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Further Reading: What is the balance sheet?

Get a free copy of the Zacks research report on Avanos Medical (AVNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.